TransmedicsTMDX
TMDX
About: TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System(OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The Company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.
Employees: 584
0
Funds holding %
of 6,823 funds
0
Analysts bullish %
of 7 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
85% more first-time investments, than exits
New positions opened: 76 | Existing positions closed: 41
56% more call options, than puts
Call options by funds: $82.4M | Put options by funds: $52.8M
10% more funds holding
Funds holding: 332 [Q2] → 364 (+32) [Q3]
8% more capital invested
Capital invested by funds: $5.25B [Q2] → $5.68B (+$436M) [Q3]
3.05% more ownership
Funds ownership: 105.77% [Q2] → 108.82% (+3.05%) [Q3]
7% more repeat investments, than reductions
Existing positions increased: 130 | Existing positions reduced: 121
36% less funds holding in top 10
Funds holding in top 10: 14 [Q2] → 9 (-5) [Q3]
Research analyst outlook
7 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$75
31%
upside
Avg. target
$106
86%
upside
High target
$125
119%
upside
7 analyst ratings
6 positive
86%
1 neutral
14%
0 negative
0%
JP Morgan Allen Gong 33% 1-year accuracy 3 / 9 met price target | 31%upside $75 | Neutral Downgraded | 17 Dec 2024 |
Piper Sandler Matt O'Brien 57% 1-year accuracy 29 / 51 met price target | 57%upside $90 | Overweight Maintained | 11 Dec 2024 |
Baird Joe Vruwink 40% 1-year accuracy 17 / 42 met price target | 110%upside $120 | Outperform Maintained | 11 Dec 2024 |
Oppenheimer Suraj Kalia 61% 1-year accuracy 14 / 23 met price target | 119%upside $125 | Outperform Maintained | 3 Dec 2024 |
Canaccord Genuity William Plovanic 74% 1-year accuracy 34 / 46 met price target | 82%upside $104 | Buy Maintained | 20 Nov 2024 |
Financial journalist opinion
Based on 48 articles about TMDX published over the past 30 days
Neutral
GlobeNewsWire
16 hours ago
TransMedics Group (TMDX) Plunges Amidst Allegations of Fraud, Organ Trafficking – Hagens Berman
SAN FRANCISCO, Jan. 20, 2025 (GLOBE NEWSWIRE) -- Shares of TransMedics, Group Inc. (NASDAQ: TMDX) suffered a sharp decline over the past two trading days following the release of a damaging report by activist short-seller Scorpion Capital. TransMedics' stock price has dropped $9.84, or 13%, since Scorpion released a report, titled “Walk Like An Egyptian,” leveling serious allegations against the company, including fraud, organ trafficking, and off-label device misuse.
Negative
Zacks Investment Research
20 hours ago
TMDX Stock Down Despite Responding to Misleading Short-Seller Report
TransMedics addresses the misleading claims made in a short-seller report issued by Scorpion Capital.
Neutral
Accesswire
21 hours ago
TransMedics Group, Inc. Is Being Investigated For Securities Law Violations And Affected Shareholders Are Urged To Contact The Schall Law Firm
LOS ANGELES, CA / ACCESS Newswire / January 20, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of TransMedics Group, Inc. ("TransMedics" or "the Company") (NASDAQ:TMDX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Neutral
Accesswire
22 hours ago
TMDX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces an Investigation into TransMedics Group, Inc. and Encourages Investors to Contact the Firm
NEW YORK CITY, NY / ACCESS Newswire / January 20, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of TransMedics Group, Inc. ("TransMedics" or "the Company") (NASDAQ:TMDX). Investors who purchased TransMedics securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/TMDX.
Neutral
Accesswire
23 hours ago
ROSEN, NATIONAL INVESTOR COUNSEL, Encourages TransMedics Group, Inc. Investors to Inquire About Securities Class Action Investigation – TMDX
NEW YORK CITY, NY / ACCESS Newswire / January 20, 2025 / WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of TransMedics Group, Inc. (NASDAQ: TMDX) resulting from allegations that TransMedics may have issued materially misleading business information to the investing public. SO WHAT: If you purchased TransMedics securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
Neutral
Accesswire
1 day ago
The Schall Law Firm Invites Investors With Losses To Join An Inquiry Into TransMedics Group, Inc. For Securities Fraud
LOS ANGELES, CA / ACCESS Newswire / January 19, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of TransMedics Group, Inc. ("TransMedics" or "the Company") (NASDAQ:TMDX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Neutral
Accesswire
1 day ago
Bronstein, Gewirtz & Grossman, LLC Is Investigating TransMedics Group, Inc. (TMDX) And Encourages Stockholders to Connect
NEW YORK CITY, NY / ACCESS Newswire / January 19, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of TransMedics Group, Inc. ("TransMedics" or "the Company") (NASDAQ:TMDX). Investors who purchased TransMedics securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/TMDX.
Neutral
PRNewsWire
1 day ago
Rosen Law Firm Encourages TransMedics Group, Inc. Investors to Inquire About Securities Class Action Investigation - TMDX
NEW YORK , Jan. 19, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of TransMedics Group, Inc. (NASDAQ: TMDX) resulting from allegations that TransMedics may have issued materially misleading business information to the investing public. So What: If you purchased TransMedics securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
Neutral
Accesswire
2 days ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of TransMedics Group, Inc. - TMDX
NEW YORK, NY / ACCESS Newswire / January 18, 2025 / Pomerantz LLP is investigating claims on behalf of investors of TransMedics Group, Inc. ("TransMedics" or the "Company") (NASDAQ:TMDX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
Neutral
GlobeNewsWire
2 days ago
TransMedics Group, Inc. Announcement: If You Have Suffered Losses in TransMedics Group, Inc. (NASDAQ: TMDX), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
NEW YORK, Jan. 18, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation on behalf of shareholders of TransMedics Group, Inc. (NASDAQ: TMDX) resulting from allegations that TransMedics may have issued materially misleading business information to the investing public.
Charts implemented using Lightweight Charts™